MarketPulse

Breakthrough Therapy Designation

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Vaxcyte, Inc.

Vaxcyte's 31-Valent Pneumococcal Vaccine Advances to Phase 3 on Strong Clinical Data

Vaxcyte publishes positive Phase 1/2 data for VAX-31, a 31-valent pneumococcal vaccine, and advances to Phase 3 trials with topline results expected Q4 2026.
PCVXPhase 3 clinical trialBreakthrough Therapy Designation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Eyes Clinical Inflection Point With Six Pivotal Readouts Ahead

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.
OCSOCSAWinvestor conferencesclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Oculis Charts Bold 2026 Path With Pipeline Milestones at Investor Conferences

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.
OCSOCSAWinvestor conferencesclinical trials
BenzingaBenzinga··Vandana Singh

Bristol Myers' Experimental Breast Cancer Treatment Demonstrates Survival Gains in Advanced Patients

Bristol Myers Squibb's experimental breast cancer drug showed survival improvements in advanced patients, though stock declined slightly following the announcement.
BMYCELGrbreast cancerPhase 3 trial